lansoprazole has been researched along with Body Weight in 8 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 9.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 9.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 5.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 5.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| " In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 5.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
| "Body weight was measured and blood was collected before and 12 weeks after H." | 1.43 | Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. ( Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J, 2016) |
| "Lansoprazole treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations." | 1.39 | Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. ( Singh, N; Sodhi, RK, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gamil, NM | 1 |
| Abd El Fattah, MA | 1 |
| Ahmed, MAE | 1 |
| Maklad, YA | 1 |
| Gamal El Din, AA | 1 |
| Eid, NI | 1 |
| Sakurai, T | 1 |
| Fujimori, S | 1 |
| Hayashida, M | 1 |
| Hanada, R | 1 |
| Akiyama, J | 1 |
| Sakamoto, C | 1 |
| Sodhi, RK | 1 |
| Singh, N | 1 |
| Yasu, T | 1 |
| Konuma, T | 1 |
| Kato, S | 1 |
| Kurokawa, Y | 1 |
| Takahashi, S | 1 |
| Tojo, A | 1 |
| Kasai, C | 1 |
| Sugimoto, K | 1 |
| Moritani, I | 1 |
| Tanaka, J | 1 |
| Oya, Y | 1 |
| Inoue, H | 1 |
| Tameda, M | 1 |
| Shiraki, K | 1 |
| Ito, M | 1 |
| Takei, Y | 1 |
| Takase, K | 1 |
| Yoshikawa, I | 1 |
| Nagato, M | 1 |
| Yamasaki, M | 1 |
| Kume, K | 1 |
| Otsuki, M | 1 |
| Gremse, D | 1 |
| Winter, H | 1 |
| Tolia, V | 1 |
| Gunasekaran, T | 1 |
| Pan, WJ | 1 |
| Karol, M | 1 |
| Chiu, YL | 1 |
| Pilmer, B | 1 |
| Book, L | 1 |
| Hendriks, JJ | 1 |
| Kester, AD | 1 |
| Donckerwolcke, R | 1 |
| Forget, PP | 1 |
| Wouters, EF | 1 |
3 trials available for lansoprazole and Body Weight
| Article | Year |
|---|---|
Repeatability of small bowel transit time in capsule endoscopy in healthy subjects.
Topics: Adult; Aged; Body Weight; Capsule Endoscopy; Celecoxib; Female; Gastrointestinal Transit; Healthy Vo | 2018 |
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Body Weight; Child; Ch | 2002 |
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; | 2001 |
5 other studies available for lansoprazole and Body Weight
| Article | Year |
|---|---|
Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimen | 2020 |
Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet.
Topics: Acetylcholinesterase; Alzheimer Disease; Analysis of Variance; Animals; Body Weight; Brain; Choleste | 2013 |
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Body Weight; Bone Marrow Transplan | 2016 |
Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Body Mass Index; Body We | 2016 |
Long-term treatment with proton pump inhibitor is associated with undesired weight gain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Blood Pressure; Body Mass Index; Body Weight; Case-Co | 2009 |